Bioactivities of anastasia black (Russian sweet pepper).
Anastasia Black (Russian sweet pepper) of Capsicum annuum L. var. angulosum Mill. (Solanaceae) was successively extracted with hexane, acetone, methanol and 70% methanol, and the extracts were further separated into a total of twenty-three fractions by silica gel or octadecylsilane (ODS; C18) column chromatography. These extracts and fractions were investigated for their cytotoxicity, anti-human immunodeficiency virus (HIV), anti-Helicobacter pylori (H. pylori), urease inhibition and multidrug resistance (MDR) reversal activity. Some fractions of hexane and acetone extracts showed higher cytotoxic activity against three human oral tumor cell lines (squamous cell carcinoma HSC-2, HSC-3, submandibular gland carcinoma HSG) than against three normal human oral cells (gingival fibroblast HGF, pulp cell HPC, periodontal ligament fibroblast HPLF), suggesting a tumor-specific cytotoxic activity. No fractions displayed anti-HIV activity, but some hydrophobic fractions showed higher anti-H. pylori activity, urease inhibition activity and MDR reversal activity. The higher MDR activity of these fractions against MDR gene-transfected L5178 mouse lymphoma T cells may possibly be due to their higher content of carotene or polyphenol. These data suggest that Anastasia Black should be further investigated as a potent supplement for cancer chemotherapy.
Shirataki
Yoshiaki
Y
Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama, Japan.
Kawase
Masami
M
Sakagami
Hiroshi
H
Nakashima
Hideki
H
Tani
Satoru
S
Tanaka
Toru
T
Sohara
Yoshitaka
Y
Schelz
Zsuzsanna
Z
Molnar
Joseph
J
Motohashi
Noboru
N
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D019380:Anti-HIV Agents / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D002212:Capsicum / Q000737:chemistry*; D002460:Cell Line; D018432:Drug Resistance, Multiple / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D009062:Mouth Neoplasms / Q000188:drug therapy; D010936:Plant Extracts / Q000494:pharmacology*; D014510:Urease / Q000037:antagonists & inhibitors
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D010936:Plant Extracts; D014510:Urease